10 participants
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2022-08-03
- Start Date:
- 2016-12-16
- Completion:
- 2018-10-11
Conditions
- Severe Combined Immunodeficiency Due to ADA Deficiency
Interventions
- GENETIC
- DRUG